The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor

Feng

et al. 2021

Diabetol Metab Syndr

Self Cite

Background Asprosin, a novel adipokine that raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) inhibitors for hypoglycemic effect and cardiovascular protection have not been fully clarified. Therefore, we conducted this study to assess change in the levels of serum asprosin after treatment with SGLT2 inhibitors in patients with newly diagnosed T2DM. Methods This study was a randomized, double-blind, placebo-controlled trial. A total of 29 participants with newly diagnosed T2DM with body mass index (BMI) ≥ 23.0 kg/m2 and haemoglobin A1c (HbA1c) levels of 58–85 mmol/mol (7.5–10%) were randomized to SGLT2 inhibitors dapagliflozin 10 mg/d (n = 19) or placebo (n = 10) treatment for 24 weeks. We analyzed asprosin concentrations by an enzyme-linked immunosorbent assay. Besides, body weight, BMI, HbA1c, fasting plasma glucose (FPG), and lipid levels were measured at baseline and 24 weeks. Results At 24 weeks, participants with SGLT2 inhibitors treatment exhibited lower levels of serum asprosin (22.87 vs 45.06 ng/ml in the placebo group; P < 0.001) after adjusting for baseline values. The levels of body weight, BMI, HbA1c, FPG, and triglyceride (TG) were decreased, while high density lipoprotein-cholesterol (HDL-C) was increased after SGLT2 inhibitors dapagliflozin treatment compared with placebo (P < 0.05 for all). Low density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were unchanged in the SGLT2 inhibitors group and placebo group. No statistical correlation was found between the levels of serum asprosin and body weight, BMI, HbA1c, FPG, and lipid levels during the SGLT2 inhibitor dapagliflozin treatment. Conclusions These findings indicated that SGLT2 inhibitors can lower serum asprosin levels and improve glucolipid and weight in patients with newly diagnosed T2DM, which may benefit the cardiovascular system. Trial registration CTR20131268; Registered 20 March 2014 CTR20150102; Registered 03 March 2015. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.

Section: Discussionmentioning

confidence: 99%

Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

Feng

et al. 2021

Diabetol Metab Syndr

Self Cite

“…However, the cardiovascular protective mechanism of SGLT2 inhibitors is not completely understood [29]. Previous studies have found that SGLT2 inhibitors may bene t the cardiovascular system through reduced atrial natriuretic peptide and brain natriuretic peptide levels [30,31]. Notwithstanding, researches have shown that adipokines involved in heart failure could be regulated by SGLT2 inhibitors [18,32].…”

Section: Discussionmentioning

confidence: 99%

Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

Feng²,

et al. 2021

Preprint

Self Cite

Background: Asprosin, a novel adipokine that raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) inhibitors for hypoglycemic effect and cardiovascular protection have not been fully clarified. Therefore, we conducted this study to assess change in the levels of serum asprosin after treatment with SGLT2 inhibitors in patients with newly diagnosed T2DM.Methods: This study was a randomized, double-blind, placebo-controlled trial. A total of 29 participants with newly diagnosed T2DM with body mass index (BMI)≥23.0 kg/m² and haemoglobin A1c (HbA1c) levels of 58~85 mmol/mol (7.5%~10%) were randomized to SGLT2 inhibitors dapagliflozin 10 mg/d (n=19) or placebo (n=10) treatment for 24 weeks. We analyzed asprosin concentrations by an enzyme-linked immunosorbent assay. Besides, body weight, BMI, HbA1c, fasting plasma glucose (FPG), and lipid levels were measured at baseline and 24 weeks. Results: At 24 weeks, participants with SGLT2 inhibitors treatment exhibited lower levels of serum asprosin (22.87 vs 45.06 ng/ml in the placebo group; P<0.001) after adjusting for baseline values. The levels of body weight, BMI, HbA1c, FPG, and triglyceride (TG) were decreased, while high density lipoprotein-cholesterol (HDL-C) was increased after SGLT2 inhibitors dapagliflozin treatment compared with placebo (P< 0.05 for all). Low density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were unchanged in the SGLT2 inhibitors group and placebo group. No statistical correlation was found between the levels of serum asprosin and body weight, BMI, HbA1c, FPG, and lipid levels during the SGLT2 inhibitor dapagliflozin treatment.Conclusions: These findings indicated that SGLT2 inhibitors can lower serum asprosin levels and improve glucolipid and weight in patients with newly diagnosed T2DM, which may benefit the cardiovascular system.Trial registration: CTR20131268 Registered 20 March 2014 CTR20150102 Registered 03 March 2015 http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml

“…SGLT2 inhibitors are distinguished from traditional hypoglycemic drugs because of its unique hypoglycemic effect and excellent cardiovascular protection [26,27].However the cardiovascular protective mechanism of SGLT2 inhibitors is not completely understood [28]. Previous studies have found that SGLT2 inhibitors may bene t the cardiovascular system through the reduced atrial natriuretic peptide and brain natriuretic peptide levels [29,30]. Notwithstanding, researches have shown that adipokines involved in heart failure could be regulated by SGLT2 inhibitors [17,31].…”

Section: Discussionmentioning

confidence: 99%

Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

Feng²,

et al. 2020

Preprint

Self Cite

BackgroundAsprosin, a novel adipokine which raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) inhibitors for hypoglycemic effect and cardiovascular protection have not been fully clarified. Therefore, we conducted this study to assess change in the levels of serum asprosin after treatment with SGLT2 inhibitors in patients with newly diagnosed T2DM.MethodsThis study was a randomized, double-blind, placebo-controlled trial. A total of 29 participants with newly diagnosed T2DM with body mass index (BMI) ≥ 23.0 kg/m² and haemoglobin A1c (HbA1c) levels of 58 ~ 85 mmol/mol (7.5%~10%) were randomized to SGLT2 inhibitors dapagliflozin 10 mg/d (n = 19) or placebo (n = 10) treatment for 24 weeks. We analyzed asprosin concentrations by an enzyme-linked immunosorbent assay. In addition, body weight, BMI, HbA1c, fasting plasma glucose (FPG), and lipid levels were measured at baseline and at 24 weeks.ResultsAt 24 weeks, participants with SGLT2 inhibitors treatment exhibited lower the levels of serum asprosin (22.87 vs 45.06 ng/ml in the placebo group; P < 0.001) after adjusting for baseline values. The levels of body weight, BMI, HbA1c, FPG and triglyceride (TG) were decreased, while high density lipoprotein-cholesterol (HDL-C) was increased after SGLT2 inhibitors dapagliflozin treatment compared with placebo (P < 0.05 for all). Low density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were unchanged in SGLT2 inhibitors group and placebo group. No statistical correlation was found between the levels of serum asprosin and body weight, BMI, HbA1c, FPG, and lipid levels during the SGLT2 inhibitor dapagliflozin treatment.ConclusionsThis study shows that SGLT2 inhibitors can decrease the levels of serum asprosin in patients with newly diagnosed T2DM, which may be involved in SGLT2 inhibitors mechanisms of improving glucose levels and reducing cardiovascular diseases risk factors.Trial registrationISRCTN, ISRCTN2013L01573. Registered 29 august 2013. http://www.icmje.org/search/?q=ISRCTN+2013L01573ISRCTN, ISRCTN2014L00001.Registered 4 January http://www.icmje.org/search/?q=ISRCTN+2014L00001